Abstract
Endometriosis is a chronic, estrogen‑dependent disorder that places a considerable physical, psychosocial,
and economic burden on women of reproductive age in India. Diagnostic delays, variation in clinical
presentation, and uncertainty regarding the optimal use of newer oral therapies continue to complicate
routine care. Elagolix, an oral gonadotropin‑releasing hormone (GnRH) receptor antagonist, has recently
been approved in India for the treatment of moderate to severe endometriosis‑associated pain; however,
guidance tailored to Indian clinical practice has been lacking.
To address this unmet need, an expert consensus was developed to provide practical recommendations for
the evaluation and management of endometriosis, with a specific focus on the positioning of elagolix in
women who are not actively pursuing fertility. A structured modified Delphi approach was used, beginning
with statement development by a steering committee, followed by regional expert panel discussions across
India and anonymous validation using a 5‑point Likert scale. Consensus was obtained with at least 75%
agreement among participating experts.
Eleven consensus statements were finalized, addressing early recognition, diagnostic strategies, empirical
medical treatment, and the appropriate selection, dosing, and monitoring of elagolix. The panel emphasized
early diagnosis, skilled transvaginal ultrasonography as first‑line imaging, and medical therapy as the
foundation of pain management in non‑fertility‑seeking women. Elagolix was recognized as an effective
oral option for selected patients, particularly those with inadequate response or intolerance to first‑line
hormonal therapies, when used with individualized risk-benefit assessment.
These consensus recommendations aim to support informed, context‑appropriate decision‑making and
optimize long‑term medical management of endometriosis‑associated pain in routine clinical practice.
Categories:
Urology, Obstetrics/Gynecology, Pain Management
Keywords
elagolix, endometriosis, endometriosis-related pain, gnrh antagonist, indian consensus
Introduction
And Background
In India, endometriosis poses a significant clinical and socioeconomic burden, affecting an estimated 42
million women
[1]
. It contributes to dysmenorrhea (77%), chronic pelvic pain (34%), and dyspareunia (23%)
[2]
. Endometriosis is also reported in up to 30% of adolescent girls presenting with secondary dysmenorrhea
[1]
. Furthermore, among infertile women undergoing diagnostic laparoscopy in Indian tertiary care centers,
endometriosis was identified in 22.3%-48.4% of women, highlighting its substantial contribution to
infertility in clinical practice
[3,4]
. Beyond its physical manifestations, endometriosis is strongly associated
with anxiety, depression, reduced productivity, and impaired social functioning, collectively contributing to
substantial socioeconomic burden and a marked decline in quality of life
[5,6]
. Pharmacological
management for endometriosis has evolved from non-steroidal anti-inflammatory drugs (NSAIDs) and
estrogen-progesterone combined pills to progestins, and later to gonadotropin-releasing hormone (GnRH)
agonists and antagonists. While NSAIDs and combined oral contraceptives (COCPs) can reduce
inflammatory symptoms, they have a limited impact on disease progression and often fail to provide
adequate and sustained control of chronic pain or address infertility
[7]
. Progestins such as dienogest have
demonstrated efficacy in reducing pelvic pain and preventing post-surgical recurrence in long-term studies
[8]
. However, bleeding irregularities and mood-related adverse effects are among the more commonly
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
15
15
Open Access Review Article
How to cite this article
Gupte S, T R, Nayyar K D, et al. (November 09, 2026) Elagolix for Endometriosis-Associated Pain: A Narrative Review and Indian Expert
Consensus. Cureus 18(11): e119395.
DOI 10.7759/cureus.119395
reported adverse events with dienogest. Changes in bone mineral density (BMD) are generally small in adult
women but may be of greater concern in adolescents and younger patients
[9]
.
Later, GnRH agonists became a mainstay for moderate to severe endometriosis pain, acting through
pituitary receptor downregulations
[10]
. Nevertheless, their use is limited by an initial symptom flare,
pronounced hypoestrogenic adverse effects (including vasomotor symptoms and bone loss), parenteral
administration, and the requirement for add-back therapy to mitigate side effects and preserve bone health
[10,11]
.
GnRH antagonists induce a rapid onset of clinical effects, without the flare-up effect seen with agonists.
GnRH antagonists have been used for the treatment of pathological conditions, such as endometriosis and
uterine fibroids. Elagolix, an oral non-peptide GnRH antagonist, was recently approved in India for
moderate to severe pain associated with endometriosis and has demonstrated its efficacy and an acceptable
safety profile in global clinical trials
[12]
.
In addition to elagolix, other oral GnRH antagonists have demonstrated efficacy in the management of
endometriosis-associated pain. Relugolix combination therapy (relugolix 40 mg, estradiol 1 mg, and
norethisterone acetate 0.5 mg) significantly improved dysmenorrhea and non-menstrual pelvic pain
compared with placebo in the phase 3 SPIRIT 1 and SPIRIT 2 trials, while minimizing bone mineral density
loss through concomitant add-back therapy
[13]
. Similarly, linzagolix demonstrated significant reductions in
endometriosis-associated pain in the phase 3 EDELWEISS 3 trial, with sustained efficacy observed in the
EDELWEISS 6 extension study
[14]
. These findings support the expanding role of oral GnRH antagonists in
endometriosis management
[15]
. However, while relugolix-containing therapies are approved in India for
uterine fibroids, they are not currently approved for endometriosis-associated pain, and linzagolix is
currently neither approved nor available in India
[16]
.
Rationale of consensus
Elagolix received regulatory approval in India in August 2024 and is supported by global evidence for the
management of endometriosis‑associated pain
[13,16]
. Currently, there are no published studies evaluating
its use in Indian patients with endometriosis. To address this evidence gap and provide context‑relevant use
in routine Indian clinical practice, an expert consensus was developed.
Review
Methodology
The development of consensus statements on the role of elagolix in endometriosis care within the Indian
clinical context required a structured, transparent, and inclusive approach to address real-world practice.
We considered a structured modified Delphi approach to generate clinically actionable consensus
statements. In this, we incorporated face-to-face discussion after the development of draft statements by
the steering committee. This allowed experts to clarify interpretations, examine evidence collectively, and
resolve disagreements through discussion. Since the 5-point Likert scale is simple, familiar, and widely used
in the modified Delphi approach, we incorporated this voting method. This helped us capture expert
agreement more clearly and in a way that aligns well with current Indian consensus practices
[17]
. This
initiative is aimed at developing consensus-based recommendations for the diagnosis and management of
endometriosis in India, with particular emphasis on women who are not currently seeking infertility
treatment
[18]
.
Steering committee
A steering committee comprising six obstetrics and gynecology experts was constituted to lead the
consensus process. Members were selected based on their clinical expertise (>15 years of experience) in
gynecology, academic contributions to the field, and willingness to participate. The steering committee was
responsible for drafting the initial consensus statements.
Development of draft consensus statements
The consensus process began with a literature review conducted by a steering committee to identify
knowledge gaps and formulate preliminary statements. A literature search was performed in PubMed,
Google Scholar, and the Cochrane Library using terms such as “elagolix,” “endometriosis,” “GnRH
antagonists,” “endometriosis in India,” “endometriosis guidelines,” “consensus,” and “endometriosis pain
management,” restricted to publications from 2015 to 2025. Based on the evidence retrieved, 13 provisional
statements were drafted across three domains: diagnosis, management of endometriosis, and role of
elagolix.
Constitution of expert panel
Considering the heterogeneity in the patient population and endometriosis care, experts were selected to
2026 Gupte et al. Cureus 18(11): e119395. DOI 10.7759/cureus.119395
2
of
14
ensure broad geographic representation across the country. A total of 74 experts were organized into 6
expert panels; a total of 12 obstetrics and gynecology specialists were part of each of the 5 expert panels,
and in the sixth expert panel, a total of 14 obstetrics and gynecology specialists were involved. Selection of
experts was based on predefined inclusion criteria, which required a minimum of 10 years of clinical
experience.
Refinement of consensus statements through regional panel meetings
A total of six round-table meetings were conducted across India to refine the preliminary consensus
statements. Sites included Chennai, Delhi, Hyderabad, Mumbai, Nagpur, and Pune. At each site, a two-hour
meeting was conducted, which followed a standardized agenda: (a) presentation of current statements with
supporting evidence (20 minutes) and (b) discussion of each statement among the experts based on real
clinical practice and guideline recommendations. Across these meetings, 42 actionable suggestions were
generated. Based on collective expert deliberation, 2 statements were removed (Appendix I), and the final
set of 11 consensus statements was established (Figure
1
).
FIGURE
1: Modified Delphi approach for the consensus development
Consensus validation
Independent validation of the finalized statements was conducted using a 5‑point Likert scale anonymous
voting process involving all 74 experts. The finalized 11 draft statements were circulated to all the experts
via mail, and responses were collected through a structured Google Form. The voting options included
“accept completely,” “accept with some reservations,” “accept with major reservations,” “reject with
reservations,” and “reject completely.” A statement was labeled “accepted” if ≥75% of respondents selected
either “accept completely” or “accept with some reservations”. Similarly, a statement was considered
rejected if 75% or more of the participants opted for “reject completely” or “reject with
reservations.” Consensus voting was used only to determine agreement with the statements.
For statements that achieved consensus, the Level of Evidence (LoE) and Strength of Evidence (SoE) were
assigned separately by the steering committee based on appraisal of the supporting literature using a
modified framework adapted from the Canadian Task Force on the Periodic Health Examination, as
summarized in Table
1
[19]
.
2026 Gupte et al. Cureus 18(11): e119395. DOI 10.7759/cureus.119395
3
of
14
Quality of Evidence
Strength of Evidence
Grade
Description
Grade
Description
I
Evidence obtained from at least one RCT
A
There is good evidence to support the
statement
II-1
Evidence from well-controlled trials without randomization
B
There is fair evidence to support the
statement
II-2
Evidence from a well-designed cohort or case-control study
C
There is poor evidence to support the
statement
II-3
Evidence from comparisons between time or place with or without
intervention
D
There is fair evidence to refute the statement
III
Opinion of experienced authorities and expert committees
E
There is good evidence to refute the
statement
TABLE
1: Quality and Strength of Evidence
RCT: randomized controlled trial
Ethical approval
Ethical approval was not required for this consensus study, as the recommendations were developed through
expert opinion and review of published literature, without the involvement of patients, human participants,
or identifiable personal data.
Expert consensus
Evaluation and Diagnosis of Endometriosis
Statement 1: Awareness, early referral, and timely management of endometriosis can reduce morbidity and
recurrence, and improve quality of life (consensus percentage: 100% (accept completely: 83.8%, accept with
some reservation: 16.2%), LoE: II-2, SoE: C).
International guidelines consistently emphasize early recognition and referral to reduce diagnostic delay
and improve outcomes. The 2022 ESHRE and 2024 NICE guidelines strongly recommend prompt evaluation
and referral to specialized care pathways to minimize disease progression and enhance quality of life
[20,21]
.
Evidence from a systematic review and meta‑analysis shows that postoperative dienogest therapy
significantly reduces recurrence after conservative surgery compared with no postoperative hormonal
treatment, underscoring the broader principle that early and appropriate medical management can mitigate
recurrence risk
[22]
. Additionally, a prospective cohort study of 205 women reported greater quality-of-life
improvement when treatment was initiated at earlier stages of disease, reinforcing the clinical value of early
intervention
[23]
. Collectively, these findings highlight that awareness, early referral, and timely
management are pivotal determinants of long‑term outcomes in endometriosis care.
Statement 2: A comprehensive evaluation with detailed menstrual, family, and systemic history is essential,
as non-specific cyclical or persistent symptoms may indicate underlying endometriosis (consensus
percentage: 100% (accept completely: 63.5%, accept with some reservation: 36.5%), LoE: III, SoE: B).
Diagnosis of endometriosis remains largely symptom-driven, and a normal ultrasound does not exclude
disease when clinical suspicion is high. ESHRE and NICE guidelines emphasize comprehensive history
taking, including menstrual characteristics, pain patterns, infertility history, and family history, to reduce
diagnostic delay
[20,21]
. A large prospective two-phase observational study across 19 hospitals (n=1,396)
demonstrated that structured symptom-based models modestly predicted any-stage disease (area under the
curve (AUC): ~0.68) and more accurately predicted stage III/IV disease (AUC: ~0.85), supporting systematic
history and symptom phenotyping to prioritize referral pathways
[24]
. Familial predisposition further
strengthens clinical suspicion. NICE-based summaries and observational data indicate that a first-degree
relative with endometriosis increases disease likelihood and may be associated with advanced-stage
presentation
[25,26]
. Implementing standardized history parameters and structured pain phenotyping in
outpatient settings may help shorten diagnostic pathways and align management with patient goals.
Statement 3: In women with suspected endometriosis, transvaginal ultrasound (TVUS) is the preferred first-
line investigation, with transabdominal ultrasound or magnetic resonance imaging (MRI) reserved for
2026 Gupte et al. Cureus 18(11): e119395. DOI 10.7759/cureus.119395
4
of
14
clinically indicated cases (consensus percentage: 91.9% (accept completely: 70.3%, accept with some
reservation: 21.6%), LoE: II-1, SoE: A).
Meta-analyses confirm that transvaginal ultrasound (TVUS) has high diagnostic accuracy for deep
endometriosis, with a pooled sensitivity of 0.85 and a specificity of 0.92, comparable to magnetic resonance
imaging (MRI) (sensitivity: 0.83, specificity: 0.95)
[27,28]
. Current ESHRE guidelines recommend skilled
TVUS as first-line imaging for suspected endometriosis, particularly for ovarian endometriomas and deep
lesions, with MRI reserved for complex mapping or equivocal findings
[20]
. Complementary evidence from
Cochrane reviews and international imaging consensus statements confirms that neither TVUS nor MRI can
reliably exclude superficial peritoneal disease, but these modalities together provide accurate mapping of
clinically significant lesions to guide management decisions
[29,30]
. Collectively, these data support an
evidence‑based, resource‑sensitive approach in which TVUS is used first, with MRI or transabdominal
ultrasound reserved for cases where clinically indicated.
Statement 4: Cancer antigen 125 (CA-125) is not recommended for routine diagnosis or exclusion of
endometriosis but may be used to monitor disease progression in conservatively managed patients
(consensus percentage: 91.9% (accept completely: 59.5%, accept with some reservation: 32.4%), LoE: I, SoE:
A).
Cancer antigen 125 (CA-125) demonstrates limited sensitivity (~52%) but relatively high specificity (~93%)
at thresholds ≥30 U/mL, functioning as a rule-in rather than rule-out test
[31]
. A Cochrane diagnostic review
concluded that no blood biomarker, including CA-125, is sufficiently accurate to replace diagnostic
evaluation or be recommended for routine clinical diagnosis
[32]
. However, limited observational data
suggest that rising CA-125 levels may correlate with recurrence in select postoperative populations. While
not suitable for screening or exclusion, CA-125 may have adjunctive value in longitudinal monitoring under
specific clinical circumstances
[20,21]
. Overall, CA-125 should not be used to exclude disease but may be
selectively employed for monitoring in individualized management strategies.
Management of Endometriosis
Statement 5: In women with clinically suspected endometriosis not seeking fertility, empirical therapy with
progestins may be initiated prior to or alongside diagnostic modalities (consensus percentage: 90.6% (accept
completely: 56.8%, accept with some reservation: 33.8%), LoE: I, SoE: A).
Major guidelines, including ESHRE, NICE, and FOGSI guidelines, endorse empirical hormonal therapy
without mandatory diagnostic laparoscopy in symptomatic women not seeking pregnancy
[20,21,33]
. In
resource-sensitive settings, accessible and cost-effective options such as progestins and levonorgestrel-
releasing intrauterine (LNG-IUS) remain pragmatic first-line choices. Empirical therapy should be aligned
with patient preferences, bleeding patterns, and tolerability, with symptomatic response guiding further
escalation
[20,21,33]
. Before initiating empirical therapy, appropriate clinical evaluation should be
undertaken to exclude alternative causes of pelvic pain and clinically significant adnexal pathology that may
require further investigation or management
[27]
.
A meta-analysis of randomized controlled trials (RCTs) demonstrated significant pain reduction compared
with placebo (standardized mean difference (SMD): -0.61; 95% confidence interval (CI): -0.77 to -0.45)
[21,34-36]
. Contemporary network meta-analyses further confirm the efficacy of progestin-only regimens
across pain domains, supporting their role as appropriate initial therapy in symptomatic patients not
pursuing pregnancy
[34,37]
.
Statement 6: In women not seeking fertility, medical therapy, including hormonal interventions, should be
offered as first-line treatment to reduce endometriosis-associated pelvic pain (consensus percentage: 95.9%
(accept completely: 60.8%, accept with reservation: 35.1%), LoE: I, SoE: A).
A 2024 network meta-analysis of 45 RCTs demonstrated consistent reductions in dysmenorrhea,
dyspareunia, and overall pelvic pain with combined oral contraceptives (COCPs) and progestins compared
with placebo
[38]
. Long-term randomized data (PRE-EMPT trial, n=405) showed sustained pain
improvement at three years with either long-acting progestogens or COCPs following surgery, supporting
the durability of hormonal suppression strategies
[39]
. Guidelines consistently recommend NSAIDs
combined with hormonal suppression as first-line therapy, reserving surgery for refractory symptoms,
complications, or fertility indications
[20,40]
. These findings reinforce medical therapy as the cornerstone of
initial management in non-fertility-seeking women, with shared decision-making central to optimizing
long-term adherence and outcomes.
Elagolix in the Management of Endometriosis Pain
Elagolix is an oral, non-peptide GnRH receptor antagonist. Elagolix 150 mg and 200 mg tablets were
approved for the management of moderate to severe pain associated with endometriosis by the US FDA in
July 2018 and by the Drugs Controller General of India (DCGI) in August 2024. In women with normal liver
2026 Gupte et al. Cureus 18(11): e119395. DOI 10.7759/cureus.119395
5
of
14
function or mild hepatic impairment (Child-Pugh A), elagolix is typically prescribed at 150 mg once daily for
up to 24 months; however, in those experiencing significant dyspareunia, a higher dose of 200 mg twice
daily may be used for a shorter duration of up to 6 months. For patients with moderate hepatic impairment
(Child-Pugh B), treatment should be limited to 150 mg once daily for no more than six months. Elagolix is
contraindicated during pregnancy, in women with osteoporosis or severe hepatic dysfunction (Child-Pugh
C), and in those receiving strong Organic Anion Transporting Polypeptide 1B1 (OATP1B1) inhibitors
[41]
.
Pharmacokinetic evaluations demonstrate rapid oral absorption (median time to peak concentration ≈ 1
hour). Plasma protein binding was 80%. Exposure (area under the plasma concentration-time curve (AUC))
and Cmax were reduced by 24 and 36%, respectively, when elagolix was administered with a high-fat meal
relative to fasting. The elimination half-life is approximately 4-6 hours. The pharmacokinetic properties of
elagolix are not affected to a clinically meaningful extent by body weight, body mass index, or race/ethnicity
[42]
.
Elagolix binds competitively to pituitary GnRH receptors, blocking endogenous GnRH signaling. Elagolix
produces rapid and dose-dependent suppression of luteinizing hormone (LH) and follicle-stimulating
hormone (FSH), resulting in reduced ovarian estradiol concentrations and attenuation of estrogen-
dependent endometriotic activity. In contrast to GnRH agonists, elagolix does not cause an initial flare and
allows graded suppression of estradiol, with median estradiol levels reduced to approximately 42 pg/mL
with 150 mg once daily and 12 pg/mL with 200 mg twice daily in phase 3 studies
[43,44]
.
In the pivotal ELARIS EM-I and EM-II trials, both 150 mg once daily and 200 mg twice daily regimens
significantly improved dysmenorrhea and non-menstrual pelvic pain compared with placebo at three
months, with sustained responses through six months. Dysmenorrhea responder rates ranged from 43.4% to
46.4% with elagolix 150 mg once daily and 72.4% to 75.8% with elagolix 200 mg twice daily, compared with
19.6% to 22.7% with placebo. Corresponding responder rates for non-menstrual pelvic pain were 49.8%-
50.4% and 54.5%-57.8% with the respective elagolix regimens, compared with 36.5% in placebo-treated
women
[43]
. Extension studies further demonstrated maintenance of response up to 12 months in a
substantial proportion of women, alongside improvements in dyspareunia and reductions in rescue
analgesic use, translating into clinically meaningful enhancement of patient-reported outcomes and quality
of life
[45]
. Across trials, elagolix was generally well tolerated; the most common adverse events included hot
flushes, headache, nausea, insomnia, and mood changes, with dose-dependent decreases in bone mineral
density (BMD) supporting defined duration limits of therapy.
Dose-dependent increases in serum lipid parameters, including low-density lipoprotein (LDL) cholesterol
and triglycerides, have also been observed with elagolix therapy
[46,47]
.
Most clinical guidelines recommend GnRH antagonists such as elagolix as a second‑line treatment for
endometriosis. A substantial number of women with endometriosis exhibit progesterone resistance, which
can limit the effectiveness of progestin‑based therapies. Elagolix provides a mechanistically appropriate
option for these patients, offering therapeutic benefit when progestins fail to produce adequate results.
Collectively, its oral administration, rapid onset, dose flexibility, and well-characterized benefit-risk profile
position elagolix as a valuable therapeutic option within individualized, long-term management strategies
for endometriosis-associated pain
[42]
.
Statement 7: There is clinical evidence supporting elagolix for the management of endometriosis-associated
pelvic pain, although it is not necessarily the first-line therapy (consensus percentage: 89.2% (accept
completely: 67.6%, accept with reservation: 21.6%), LoE: I, SoE: A).
Phase 3 trials of elagolix demonstrated significant reductions in dysmenorrhea and non-menstrual pelvic
pain with elagolix compared to placebo at three months and sustained till six months
[43]
. A systematic
review/meta‑analysis validates these benefits across pain domains (overall pain, dysmenorrhea,
non‑menstrual pelvic pain, and dyspareunia), while noting higher rates of non‑serious adverse events
relative to placebo
[44]
. Long-term extension studies demonstrate sustained pain reduction for up to 12
months; however, dose‑related decreases in BMD may occur and require monitoring of bone health
[45]
.
These findings establish elagolix as an effective therapeutic option, typically positioned after failure or
intolerance of first-line hormonal therapies.
Statement 8: Elagolix 150 mg once daily is recommended for moderate to severe pain associated with
endometriosis for up to 24 months. Elagolix 200 mg BID is a considerable option for moderate to severe pain
associated with dyspareunia for 6 months, followed by 150 mg once daily (consensus percentage: 93.3%
(accept completely: 67.6%, accept with reservation: 25.7%), LoE: I, SoE: A).
Dosing of elagolix should be individualized according to symptom severity and patient characteristics. The
150 mg once-daily regimen may be administered for up to 24 months in women with moderate symptoms,
whereas the 200 mg twice-daily regimen is recommended for up to 6 months in those with severe pain,
particularly when dyspareunia is prominent. Limitation of treatment duration is dose-dependent and driven
by a reduction in BMD due to reduced estrogen level; elagolix is contraindicated in severe hepatic
2026 Gupte et al. Cureus 18(11): e119395. DOI 10.7759/cureus.119395
6
of
14
impairment and requires restriction in moderate hepatic impairment
[43,46]
.
Efficacy and dose selection are supported by phase 3 trials and meta-analyses. In the ELARIS EM-I and EM-II
studies (N≈1,700), both 150 mg once daily and 200 mg twice daily significantly improved dysmenorrhea and
non-menstrual pelvic pain compared with placebo at 3-6 months, demonstrating clear dose-dependent
effects. Improvements in dyspareunia were more pronounced and consistent with the 200 mg twice-daily
regimen, supporting its use in women with prominent dyspareunia. Long-term extension studies (EM-III
and EM-IV) confirmed maintenance of pain relief for up to 12 months, while also demonstrating dose-
related declines in BMD that justify defined duration limits and step-down strategies
[43,45,46]
.
Statement 9: Elagolix can be considered as an alternative option for women with endometriosis-associated
pelvic pain not responding to prior therapies (consensus percentage: 89.2% (accept completely: 62.2%,
accept with reservation: 27.0%), LoE: II-3, SoE: B).
For women with inadequate response or intolerance to prior therapies (e.g., progestins/COCPs), elagolix is a
reasonable alternative, supported by extension studies (EM-III and EM-IV) demonstrating sustained efficacy
and acceptable safety over 12 months. Advantages include rapid onset, no flare, oral administration,
predictable reversibility, and the option of add‑back therapy to support longer‑term tolerability
[45,48]
. In
India, elagolix provides a non‑injectable choice aligned with patient preferences; selection should consider
cost, access, and monitoring capacity
[49,50]
.
Statement 10: Compared to GnRH agonists, elagolix 150 mg once daily for up to 24 months reported lower
bone mineral density-related side effects, minimizing the need for add-back therapy (consensus percentage:
91.9% (accept completely: 55.4%, accept with reservation: 36.5%), LoE: III, SoE: C).
Elagolix shows dose-dependent BMD reduction, smaller at 150 mg QD than at 200 mg BID, and does not
mandate add-back therapy as per label
[46,48]
.
A recent systematic review and meta-analysis of randomized controlled trials reported significantly less
bone mineral density reduction with GnRH antagonists than with GnRH agonists. However, bone mineral
density changes remain dose- and duration-dependent and should be considered when selecting treatment
duration and monitoring strategies
[51]
.
Emerging evidence suggests that concomitant add-back therapy (estradiol 1 mg plus norethindrone acetate
0.5 mg) may attenuate BMD loss during extended treatment, particularly when higher doses are used
[52]
.
Accordingly, clinicians should proactively counsel patients that elagolix may cause dose‑related
hypoestrogenic adverse effects, most commonly hot flushes/night sweats, headache, nausea, insomnia, and
mood changes, which are generally more frequent at higher doses. Given the dose‑ and duration‑dependent
impact on bone mineral density, therapy should be aligned to the lowest effective dose and appropriate
duration, with bone health risk assessment (and BMD assessment when clinically indicated) incorporated
into follow‑up, particularly in women with additional risk factors
[46,47,53]
.
Patients should be informed that menstrual bleeding may decrease or stop, which can reduce the ability to
recognize pregnancy, and pregnancy testing should be performed if pregnancy is suspected. We recommend
advising effective non‑hormonal contraception during treatment and for 28 days after discontinuation and
noting that estrogen‑containing contraceptives may reduce elagolix efficacy. Clinicians should also counsel
on red flag symptoms and promptly evaluate patients with new or worsening depression/anxiety or suicidal
ideation, or symptoms suggestive of liver injury (e.g., jaundice or dark urine), with reassessment of benefit
and risk if such events occur
[46,47,53]
.
Statement 11: Elagolix may be considered as a first-line therapy for selected patients with endometriosis,
such as those with dyspareunia (consensus percentage: 90.6% (accept completely: 56.8%, accept with
reservation: 33.8%), LoE: I, SoE: B).
Although guidelines recommend progestins/COCPs as first-line therapy, the expert panel acknowledged
scenarios in which elagolix may be an appropriate initial option. These include intolerance or
contraindication to estrogen- or progestin-based therapies, patient preference for a non-contraceptive oral
agent, or the need for rapid, reversible ovarian suppression
[20]
.
Progestin intolerance is clinically relevant in routine practice. Cohort data with dienogest report
discontinuation rates approaching 20% within the first year, most commonly due to irregular bleeding, mood
changes, reduced libido, and vaginal dryness
[54,55]
.
In such women, an oral GnRH antagonist offers a non‑progestin mechanism of action. However, as current
guidelines do not formally position elagolix as first-line therapy, its use in this context should be
individualized and supported by shared decision-making, with appropriate documentation of risks and
2026 Gupte et al. Cureus 18(11): e119395. DOI 10.7759/cureus.119395
7
of
14
benefits (Figure
2
and Figure
3
)
[31,46]
.
FIGURE
2: Algorithm for the management of endometriosis
ART: assisted reproductive technology, CA-125: cancer antigen 125, MRI: magnetic resonance imaging, NSAID:
non-steroidal anti-inflammatory drug, OC: oral contraceptive, TVUS: transvaginal ultrasound, TAUS:
transabdominal ultrasound
FIGURE
3: Elagolix use in endometriosis management
BMD: bone mineral density, LFT: liver function test
2026 Gupte et al. Cureus 18(11): e119395. DOI 10.7759/cureus.119395
8
of
14
To support shared decision‑making and safe, appropriate use of elagolix, patients should be counselled on
expected hypoestrogenic effects, contraception requirements, and red flag symptoms. A brief checklist of
routine practice is provided in Table
2
.
Before initiating
Exclude pregnancy (or start within 7 days of menses)
Counsel: bleeding may reduce/stop, so pregnancy may be harder to recognize
Non-hormonal contraception during treatment and for 28 days after stopping
Consider/check baseline lipid profile
Bone risk screen; BMD scan (DEXA) if risk factors for osteoporosis or when treatment beyond 12 months is anticipated; do not use in
known osteoporosis
Mood history screen (depression/anxiety/suicidality)
Review liver history; counsel on liver injury symptoms
Discuss treatment cost/affordability
During treatment
Explain common AEs: hot flush/night sweats, headache, nausea, insomnia, mood changes
Bone protection: calcium/vitamin D + weight-bearing activity
If continuing in risk patients, repeat BMD at ~1 year (as clinically indicated)
Follow-up and stop/urgent review
Schedule follow-up at 4-6 weeks and ~3 months
Stop if pregnant; evaluate promptly if pregnancy suspected
Urgent review: new/worsening depression, anxiety, suicidal thoughts/behavior
Urgent review: jaundice/dark urine or other liver injury symptoms
TABLE
2: Checklist for patient counseling for elagolix
BMD: bone mineral density, AE: adverse events
Final Consensus Statements
Based on evidence, experts agreed on the following statements in the meeting (Table
3
).
2026 Gupte et al. Cureus 18(11): e119395. DOI 10.7759/cureus.119395
9
of
14
Consensus statements
Consensus
percentage
LoE
and
SoE
Section 1: Evaluation and diagnosis of endometriosis
1
Awareness, early referral, and timely management of endometriosis can reduce morbidity and recurrence, and
improve quality of life.
100%
II-2,
C
2
A comprehensive evaluation with detailed menstrual, family, and systemic history is essential, as non-specific
cyclical or persistent symptoms may indicate underlying endometriosis.
100%
III,
B
3
In women with suspected endometriosis, transvaginal ultrasound is the preferred first-line investigation, with
transabdominal ultrasound or MRI reserved for clinically indicated cases.
91.9%
II-1,
A
4
CA-125 is not recommended for routine diagnosis or exclusion of endometriosis but may be used to monitor
disease progression in conservatively managed patients
91.9%
I, A
Section 2: Management of endometriosis and role of elagolix
5
In women with clinically suspected endometriosis not seeking fertility, empirical therapy with progestins may be
initiated prior to or alongside diagnostic modalities.
90.6%
I, A
6
In women not seeking fertility, medical therapy, including hormonal interventions, should be offered as first-line
treatment to reduce endometriosis-associated pelvic pain.
95.9%
I, A
7
There is clinical evidence supporting elagolix for the management of endometriosis-associated pelvic pain,
although it is not necessarily the first-line therapy.
89.2%
I, A
8
Elagolix 150 mg OD is recommended for moderate to severe pain associated with endometriosis for up to 24
months. Elagolix 200 mg BID is a considerable option for moderate to severe pain associated with dyspareunia
for 6 months, followed by 150 mg OD.
93.3%
I, A
9
Elagolix can be considered as an alternative option for women with endometriosis-associated pelvic pain not
responding to prior therapies.
89.2%
II-3,
B
10
Compared to GnRH agonists, elagolix 150 mg once daily for up to 24 months reported lower bone mineral
density-related side effects, minimizing the need for add-back therapy.
91.9%
III,
C
11
Elagolix may be considered as a first-line therapy for selected patients with endometriosis, such as those with
dyspareunia.
90.6%
I, B
TABLE
3: Final consensus statements
All recommendations regarding elagolix in this consensus apply to adult women (≥18 years of age) unless otherwise specified.
CA-125: cancer antigen 125, LoE: Level of Evidence, MRI: magnetic resonance imaging, OD: once daily, SoE: Strength of Evidence
Limitations
This expert consensus has certain limitations. First, the recommendations are based on a structured
literature review and expert opinion rather than a formal systematic review or meta-analysis, which may
introduce selection bias. Although the level and strength of evidence were graded using a modified
framework adapted from the Canadian Task Force on the Periodic Health Examination, the grading process
relied on expert assessment and was not supported by a formal systematic evidence review, which may
introduce subjectivity in evidence interpretation and recommendation development.
Second, the consensus process involved a single round of anonymous voting following regional expert
discussions. While this approach facilitated broad participation, it may have limited opportunities for
iterative refinement of statements and reassessment of areas of disagreement. The expert panel consisted
exclusively of obstetricians and gynecologists with experience in endometriosis management and therefore
may not fully reflect the perspectives of other relevant stakeholders, including reproductive
endocrinologists, pain specialists, primary care physicians, and multidisciplinary care teams.
Third, patient representatives were not involved in the consensus development process. Consequently,
patient preferences, experiences, and patient-reported outcomes may not be fully represented in the final
recommendations.
2026 Gupte et al. Cureus 18(11): e119395. DOI 10.7759/cureus.119395
10
of
14
Fourth, although a structured consensus methodology and anonymous expert voting were employed to
minimize bias, the possibility of perceived conflict of interest cannot be completely excluded.
Fifth, variability in real-world clinical practices and limited India-specific data on elagolix may affect the
generalizability of the recommendations. Furthermore, the scope of this consensus was focused specifically
on elagolix and did not include a systematic comparative evaluation of other GnRH antagonists or
alternative medical therapies for endometriosis, which may limit broader treatment comparisons.
Finally, as emerging evidence continues to evolve, some recommendations may require future updates to
remain aligned with the latest clinical data and guidelines.
Conclusions
Endometriosis continues to impose a substantial clinical and socioeconomic burden in India, with persistent
delays in diagnosis and variability in therapeutic pathways. In the absence of Indian patient-specific data on
elagolix, this consensus was developed to provide structured, context-relevant guidance for its rational
integration into routine practice, particularly among women not seeking fertility. The consensus
emphasized the “diagnose early, treat early” paradigm, prioritizing skilled transvaginal ultrasonography for
timely detection and initiating empirical hormonal therapy in appropriate non-fertility-seeking women to
reduce morbidity, limit recurrence, and improve quality of life. Within this framework, elagolix represents
an oral GnRH antagonist that offers rapid, titratable suppression without flare, aligning well with patient
preferences for non‑injectable, reversible therapy in routine practice. Across phase 3 trials and extension
studies, elagolix has demonstrated clinically meaningful reductions in dysmenorrhea and non‑menstrual
pelvic pain, with the 200
mg BID regimen showing utility when dyspareunia is a prominent symptom; the
150
mg OD regimen provides durable control for up to 24
months in appropriately selected patients. When
individualized through shared decision‑making, considering bone health, mood, hepatic status, and
contraceptive counseling, elagolix can help more patients realize the benefits of medical management
earlier in their disease course.
This consensus provides practical direction for patient selection, dosing, monitoring, and positioning of
elagolix in endometriosis care. Future research should generate real-world Indian data, clarify optimal
sequencing and add-back strategies, and explore the role of GnRH antagonism in related gynecologic
conditions such as adenomyosis and uterine fibroids, thereby strengthening the long-term evidence base for
personalized endometriosis management.
Appendices
Appendix I
The two statements that were excluded from the final consensus are shown in Table
4
.
Statement
Consensus outcome
Elagolix may be considered for heavy menstrual bleeding associated with uterine
leiomyomas in premenopausal women.
Excluded from final consensus due to off-
label indication
GnRH antagonists (elagolix) may be considered for uterine fibroids with coexisting
adenomyosis.
Excluded from final consensus due to off-
label indication
TABLE
4: Statements excluded from the final consensus
Additional Information
Author Contributions
All authors have reviewed the final version to be published and agreed to be accountable for all aspects of the
work.
Acquisition, analysis, or interpretation of data:
Kamal Kumar, Rooma Sinha, Jeyarani Kamaraj, Jayanthi
Reddy, Mala Raj, Parag Biniwale, Sushma Deshmukh, Chaitanya Ganpule, Sachin Kulkarni, Neeraj Kumar, K
D. Nayyar
Drafting of the manuscript:
Kamal Kumar, Neeraj Kumar
Supervision:
Kamal Kumar, Onkar C. Swami
2026 Gupte et al. Cureus 18(11): e119395. DOI 10.7759/cureus.119395
11
of
14
Concept and design:
Sanjay Gupte, Ramanidevi T, PM Gopinath, Girija Wagh, Onkar C. Swami, Shivani S.
Gour
Critical review of the manuscript for important intellectual content:
Sanjay Gupte, Ramanidevi T, PM
Gopinath, Rooma Sinha, Jeyarani Kamaraj, Jayanthi Reddy, Mala Raj, Girija Wagh, Parag Biniwale, Sushma
Deshmukh, Chaitanya Ganpule, Sachin Kulkarni, Onkar C. Swami, K D. Nayyar, Shivani S. Gour
Disclosures
Conflicts of interest:
In compliance with the ICMJE uniform disclosure form, all authors declare the
following:
Payment/services info:
All authors have declared that no financial support was received from
any organization for the submitted work.
Financial relationships:
All declare(s) Funding for publication
from Alembic Pharmaceuticals Ltd. Alembic Pharmaceuticals Ltd. supported the article processing and
publication charges for this manuscript. Dr. Onkar Swami, Dr. Kamal Kumar, and Mr. Neeraj Kumar
declare(s) employment from Alembic Pharmaceuticals Ltd., which actively markets Elagolix.
Other
relationships:
All authors have declared that there are no other relationships or activities that could appear
to have influenced the submitted work.
Acknowledgements
The authors extend sincere thanks to the 74 clinicians who actively participated in the discussions during
the expert meeting and were instrumental in the development of the consensus statements presented in this
manuscript. The authors would also like to thank Dr. Heena Bhojwani and Ms. Divya Aher for reviewing,
editing, and submitting this manuscript. The artificial intelligence (AI) tool Microsoft Copilot was utilized to
assist with language refinement and grammar correction.
References
1
.
Gajbhiye RK:
Endometriosis and inflammatory immune responses: Indian experience
. Am J Reprod
Immunol. 2023, 89:e13590.
10.1111/aji.13590
2
.
Bendigeri T, Warty N, Sawant R, et al.:
Endometriosis: clinical experience of 500 patients from India
. Indian
Pract. 2015, 68:33-40.
3
.
Varghese N, Shanmugam I, Sivamani H, Durairaj A:
Prevalence and risk factors of endometriosis among
infertile women in a tertiary care center in South India
. Cureus. 2024, 16:e71772.
10.7759/cureus.71772
4
.
Mishra VV, Gaddagi RA, Aggarwal R, Choudhary S, Sharma U, Patel U:
Prevalence; characteristics and
management of endometriosis amongst infertile women: a one year retrospective study
. J Clin Diagn Res.
2015, 9:QC01-3.
10.7860/JCDR/2015/13687.6125
5
.
Perricos A, Wenzl R:
Recent advances in endometriosis pathophysiology and pharmacological treatment
. Int
J Mol Sci. 2024, 25:
10.3390/ijms25126575
6
.
Elizur SE, Mostafa J, Berkowitz E, Orvieto R:
Endometriosis and infertility: pathophysiology, treatment
strategies, and reproductive outcomes
. Arch Gynecol Obstet. 2025, 312:1037-48.
10.1007/s00404-025-
08124-1
7
.
Rafique S, Decherney AH:
Medical management of endometriosis
. Clin Obstet Gynecol. 2017, 60:485-96.
10.1097/GRF.0000000000000292
8
.
Capezzuoli T, Vannuccini S, Mautone D, et al.:
Long-term hormonal treatment reduces repetitive surgery for
endometriosis recurrence
. Reprod Biomed Online. 2021, 42:451-6.
10.1016/j.rbmo.2020.09.018
9
.
Murji A, Biberoğlu K, Leng J, Mueller MD, Römer T, Vignali M, Yarmolinskaya M:
Use of dienogest in
endometriosis: a narrative literature review and expert commentary
. Curr Med Res Opin. 2020, 36:895-907.
10.1080/03007995.2020.1744120
10
.
Surrey ES:
GnRH agonists in the treatment of symptomatic endometriosis: a review
. F S Rep. 2023, 4:40-5.
10.1016/j.xfre.2022.11.009
11
.
Donnez J, Dolmans MM:
GnRH antagonists with or without add-back therapy: a new alternative in the
management of endometriosis?
. Int J Mol Sci. 2021, 22:
10.3390/ijms222111342
12
.
Martínez-Núñez EN, Carvallo-Ruiz DE, Núñez-Troconis JT:
Gynecological uses of GnRH antagonists: review
article
. Obstet Gynecol Int J. 2022, 13:226-38.
10.15406/ogij.2022.13.00654
13
.
Giudice LC, As-Sanie S, Arjona Ferreira JC, et al.:
Once daily oral relugolix combination therapy versus
placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind,
studies (SPIRIT 1 and 2)
. Lancet. 2022, 399:2267-79.
10.1016/S0140-6736(22)00622-5
14
.
Donnez J, Becker C, Taylor H, et al.:
Linzagolix therapy versus a placebo in patients with endometriosis-
associated pain: a prospective, randomized, double-blind, phase 3 study (EDELWEISS 3)
. Hum Reprod. 2024,
39:1208-21.
10.1093/humrep/deae076
15
.
Donnez J, Taylor HS, Taylor RN, et al.:
Treatment of endometriosis-associated pain with linzagolix, an oral
gonadotropin-releasing hormone-antagonist: a randomized clinical trial
. Fertil Steril. 2020, 114:44-55.
10.1016/j.fertnstert.2020.02.114
16
.
Central Drugs Standard Control Organisation: CDSCO approved drugs/vaccines/r-DNA/blood product
.
(2026). Accessed: August 7, 2026:
https://cdscoonline.gov.in/CDSCO/cdscoDrugs
.
17
.
Nasa P, Jain R, Juneja D:
Delphi methodology in healthcare research: how to decide its appropriateness
.
World J Methodol. 2021, 11:116-29.
10.5662/wjm.v11.i4.116
18
.
Murphy MK, Black NA, Lamping DL, McKee CM, Sanderson CF, Askham J, Marteau T:
Consensus
development methods, and their use in clinical guideline development
. Health Technol Assess. 1998, 2:1-88.
10.3310/hta2030
19
.
The Periodic Health Examination: 2. 1984 update. Canadian Task Force on the Periodic Health Examination
.
2026 Gupte et al. Cureus 18(11): e119395. DOI 10.7759/cureus.119395
12
of
14
Can Med Assoc J. 1984, 130:1278-85.
20
.
Becker CM, Bokor A, Heikinheimo O, et al.:
ESHRE guideline: endometriosis
. Hum Reprod Open. 2022,
2022:hoac009.
10.1093/hropen/hoac009
21
.
Endometriosis: Diagnosis and Management
. National Institute for Health and Care Excellence (NICE),
London; 2024.
22
.
Zakhari A, Edwards D, Ryu M, Matelski JJ, Bougie O, Murji A:
Dienogest and the risk of endometriosis
recurrence following surgery: a systematic review and meta-analysis
. J Minim Invasive Gynecol. 2020,
27:1503-10.
10.1016/j.jmig.2020.05.007
23
.
Kaveh M, Moghadam MN, Safari M, Chaichian S, Kashi AM, Afshari M, Sadegi K:
The impact of early
diagnosis of endometriosis on quality of life
. Arch Gynecol Obstet. 2025, 311:1415-21.
10.1007/s00404-025-
07999-4
24
.
Nnoaham KE, Hummelshoj L, Kennedy SH, Jenkinson C, Zondervan KT:
Developing symptom-based
predictive models of endometriosis as a clinical screening tool: results from a multicenter study
. Fertil Steril.
2012, 98:692-701.e5.
10.1016/j.fertnstert.2012.04.022
25
.
Metzler JM, Imesch P, Dietrich H, Knobel C, Portmann L, Neumeier MS, Merki-Feld GS:
Impact of family
history for endometriosis, migraine, depression and early menopause on endometriosis symptoms,
localization and stage: a case control study
. Eur J Obstet Gynecol Reprod Biol. 2024, 293:36-43.
10.1016/j.ejogrb.2023.12.016
26
.
Rajesh S, Mehmeti A, Smith-Walker T, Kendall B:
Diagnosis and management of endometriosis: summary
of updated NICE guidance
. BMJ. 2025, 388:q2782.
10.1136/bmj.q2782
27
.
Daniilidis A, Grigoriadis G, Dalakoura D, D'Alterio MN, Angioni S, Roman H:
Transvaginal ultrasound in the
diagnosis and assessment of endometriosis-an overview: how, why, and when
. Diagnostics (Basel). 2022,
12:
10.3390/diagnostics12122912
28
.
Xu Z, Li Y, Wang Y, Wan Y, Chen J:
Transvaginal ultrasound and magnetic resonance imaging in detecting
rectosigmoid deep infiltrating endometriosis: a comparative meta-analysis
. Front Med (Lausanne). 2025,
12:1552185.
10.3389/fmed.2025.1552185
29
.
Nisenblat V, Bossuyt PM, Farquhar C, Johnson N, Hull ML:
Imaging modalities for the non-invasive
diagnosis of endometriosis
. Cochrane Database Syst Rev. 2016, 2:CD009591.
10.1002/14651858.CD009591.pub2
30
.
Condous G, Gerges B, Thomassin-Naggara I, et al.:
Non-invasive imaging techniques for diagnosis of pelvic
deep endometriosis and endometriosis classification systems: an international consensus statement()
. Hum
Reprod Open. 2024, 2024:hoae029.
10.1093/hropen/hoae029
31
.
Hirsch M, Duffy J, Davis CJ, Nieves Plana M, Khan KS:
Diagnostic accuracy of cancer antigen 125
for endometriosis: a systematic review and meta-analysis
. BJOG. 2016, 123:1761-8.
10.1111/1471-
0528.14055
32
.
Nisenblat V, Bossuyt PM, Shaikh R, et al.:
Blood biomarkers for the non-invasive diagnosis of endometriosis
.
Cochrane Database Syst Rev. 2016, 2016:CD012179.
10.1002/14651858.CD012179
33
.
Barbara G, Buggio L, Facchin F, Vercellini P:
Medical treatment for endometriosis: tolerability, quality of
life and adherence
. Front Glob Womens Health. 2021, 2:729601.
10.3389/fgwh.2021.729601
34
.
Mitchell JB, Chetty S, Kathrada F:
Progestins in the symptomatic management of endometriosis: a meta-
analysis on their effectiveness and safety
. BMC Womens Health. 2022, 22:526.
10.1186/s12905-022-02122-0
35
.
FOGSI-ICOG Good Clinical Practice Recommendations (GCPR) Updates in Endometriosis Management
.
Endometriosis Committee, 2026.
36
.
Vercellini P, Buggio L, Berlanda N, Barbara G, Somigliana E, Bosari S:
Estrogen-progestins and progestins for
the management of endometriosis
. Fertil Steril. 2016, 106:1552-71.e2.
10.1016/j.fertnstert.2016.10.022
37
.
As-Sanie S, Mackenzie SC, Morrison L, Schrepf A, Zondervan KT, Horne AW, Missmer SA:
Endometriosis: a
review
. JAMA. 2025, 334:64-78.
10.1001/jama.2025.2975
38
.
Csirzó Á, Kovács DP, Szabó A, et al.:
Comparative analysis of medical interventions to alleviate
endometriosis-related pain: a systematic review and network meta-analysis
. J Clin Med. 2024,
13:
10.3390/jcm13226932
39
.
Cooper KG, Bhattacharya S, Daniels JP, et al.:
Long acting progestogens versus combined oral contraceptive
pill for preventing recurrence of endometriosis related pain: the PRE-EMPT pragmatic, parallel group, open
label, randomised controlled trial
. BMJ. 2024, 385:e079006.
10.1136/bmj-2023-079006
40
.
Patel M:
Recent trends in medical management of endometriosis
. J Obstet Gynaecol India. 2024, 74:479-83.
10.1007/s13224-024-02097-y
41
.
Lamb YN:
Elagolix: first global approval
. Drugs. 2018, 78:1501-8.
10.1007/s40265-018-0977-4
42
.
Shebley M, Polepally AR, Nader A, et al.:
Clinical pharmacology of elagolix: an oral gonadotropin-releasing
hormone receptor antagonist for endometriosis
. Clin Pharmacokinet. 2020, 59:297-309.
10.1007/s40262-
019-00840-7
43
.
Taylor HS, Giudice LC, Lessey BA, et al.:
Treatment of endometriosis-associated pain with elagolix, an oral
GnRH antagonist
. N Engl J Med. 2017, 377:28-40.
10.1056/NEJMoa1700089
44
.
Quishpe M, Endara-Mina J, Caizapanta J, et al.:
Efficacy of elagolix and relugolix for the treatment of pelvic
pain in patients with endometriosis: a systematic review
. Cureus. 2025, 17:e92149.
10.7759/cureus.92149
45
.
Surrey E, Taylor HS, Giudice L, et al.:
Long-term outcomes of elagolix in women with endometriosis: results
from two extension studies
. Obstet Gynecol. 2018, 132:147-60.
10.1097/AOG.0000000000002675
46
.
Elagolix prescribing information
. (2026). Accessed: August 7, 2026:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210450s004s005s006lbl.pdf
.
47
.
Leyland N, Estes SJ, Lessey BA, Advincula AP, Taylor HS:
A clinician’s guide to the treatment of
endometriosis with elagolix
. J Womens Health (Larchmt). 2021, 30:569-78.
10.1089/jwh.2019.8096
48
.
Archer DF, Watts N, Gallagher C, et al.:
Long-term effect of elagolix on bone mineral density: results from
two phase 3 extension studies in women with endometriosis-associated pain
. Fertil Steril. 2017, 108:E95.
10.1016/j.fertnstert.2017.07.292
49
.
Betiuk Z, Błażyca M, Bartoszczyk M, Kutyła K, Gierulska N, Tarkowski R, Kułak K:
Current evidence and
emerging directions in endometriosis pharmacotherapy: a systematic review of recent advances
. J Clin Med.
2026 Gupte et al. Cureus 18(11): e119395. DOI 10.7759/cureus.119395
13
of
14
2026, 15:
10.3390/jcm15187238
50
.
Wang ST, Johnson SJ, Mitchell D, Soliman AM, Vora JB, Agarwal SK:
Cost-effectiveness of elagolix versus
leuprolide acetate for treating moderate-to-severe endometriosis pain in the USA
. J Comp Eff Res. 2019,
8:337-55.
10.2217/cer-2018-0124
51
.
Liu T, Cai Y, Li M, et al.:
Gonadotropin-releasing hormone antagonists versus agonists for endometriosis: a
systematic review and meta-analysis of randomized controlled trials
. Front Endocrinol (Lausanne). 2026,
17:1979544.
10.3389/fendo.2026.1979544
52
.
Miller CE, Kim JH, Kroll R, et al.:
Efficacy, tolerability, and bone density outcomes of elagolix with add-back
therapy for endometriosis-associated pain: twelve months of an ongoing randomized phase 3 trial
. Am J
Obstet Gynecol. 2024, 231:630.e1-630.e13.
10.1016/j.ajog.2024.06.040
53
.
ORILISSA patient counseling aid
. (2026). Accessed: August 7, 2026:
https://www.orilissa.com/hcp/endometriosis-specialist-resources/patient-counseling
.
54
.
La Torre F, Vannuccini S, Toscano F, Gallucci E, Orlandi G, Manzi V, Petraglia F:
Long-term treatment for
endometriosis with dienogest: efficacy, side effects and tolerability
. Gynecol Endocrinol. 2024, 40:2336121.
10.1080/09513590.2024.2336121
55
.
Nirgianakis K, Vaineau C, Agliati L, McKinnon B, Gasparri ML, Mueller MD:
Risk factors for non-response
and discontinuation of dienogest in endometriosis patients: a cohort study
. Acta Obstet Gynecol Scand.
2021, 100:30-40.
10.1111/aogs.13969
2026 Gupte et al. Cureus 18(11): e119395. DOI 10.7759/cureus.119395
14
of
14
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.